Key facts
- This page summarizes Michael Vasconcelles's Form 3 filing for Day One Biopharmaceuticals, Inc. (DAWN).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Jun 2025, 19:41.
Michael Vasconcelles - 16 Jun 2025 Form 3 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)
- Reporting relationship
- Head of Research and Dev.
- Issuer ticker
- DAWN
- Reported as of
- 16 Jun 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Jun 2025, 19:41:26 UTC
- Prior SEC filing
- 06 Jun 2025
- Next SEC filing
- 30 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles N. York II, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Vasconcelles filed Form 3 for Day One Biopharmaceuticals, Inc. (DAWN) on 18 Jun 2025.
Change
- Previous filing in this sequence was filed on 06 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001734755
Primary reporting owner
VASCONCELLES MICHAEL
- Relationship
- Head of Research and Dev.
- Address
- C/O DAY ONE BIOPHARMACEUTICALS, INC., 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
- Signature
- /s/ Charles N. York II, as Attorney-in-Fact
- Signature date
- 18 Jun 2025
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.